 |
||
| HOME | ||
|
||
| Acute Myelogenous Leukemia (AML) |
||
|
||
| Other Leukemia Types (ALL / CLL / CML / HCL) |
||
|
||
| Myelodysplastic Syndrome | ||
|
||
| Symptoms and Diagnosis | ||
|
||
| Leukemia Treatment Options | ||
|
||
| " Chemotherapy | ||
|
||
| " Blood Stem Cell Transplants | ||
|
||
| " Radiation and Surgery | ||
|
||
| " Chemo Side Effects | ||
|
||
| " Clinical Trials Info | ||
|
||
| " Coping with Leukemia | ||
|
||
| " What to Ask Your Doctor | ||
|
||
| Financial Assistance | ||
|
||
| At Risk Jobs/Exposure | ||
|
||
| Leukemia Resources | ||
|
||
| Survivor's Story | ||
|
||
| Leukemia News | ||
|
||
|
Search for information:
|
||
 |
Blood Cancer &
|
 |
Leukemia Cancer Information
|
Leukemia Cancer News - Return to Menu Arsenic Trioxide & MDS: Leukemia Arsenic trioxide in patients with myelodysplastic syndromes (MDS): Preliminary results of a phase II clinical study. A. F. List, G. J. Schiller, J. Mason, D. Douer, R. Ellison; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; University of California, Los Angeles, CA; Scripps Cancer Center, San Diego, CA; USC/Norris Cancer Center, Los Angeles, CA; Cell Therapeutics, Inc, Seattle, WA Abstract: Background: Trisenox (arsenic trioxide ¨C ATO) is a novel anticancer agent approved for the treatment of relapsed or refractory acute promyelocytic leukemia. ATO has unique mechanisms of action that impact apoptotic threshold and differentiation in leukemia cell lines and hematopoietic malignancies. To investigate the activity of ATO in MDS, we performed a study in pts from Low/Int-1 (LR) and Int-2/High risk (HR) IPSS categories. Methods: Pts received ATO at 0.25 mg/kg via a 1-2 hour IV infusion, Monday to Friday, 2 consecutive wks every 28 days. Disease response and toxicity were assessed using the International Working Group (IWG) criteria and NCI CTC v2, respectively. Results: 53 pts are enrolled: 4 received no study drug and 3 are too early in treatment to assess. Among the 46 evaluable pts (29 M/17 F; median age 69, [35-93]), FAB categories were RA (6 pts), RARS (9), RAEB (18), RAEB-t (11), and CMML (2). Twenty-five pts were HR and 21 were LR MDS. The median interval from diagnosis to first dose was 7 months (0-81). Thirty-five pts were transfusion-dependent (TD). Hematologic responses were observed in 12 of 46 evaluable pts (26%); 8/21 LR pts (38%), and 4/25 HR pts (16%). Responses included 9 erythroid (5 major, including 1 CR), 3 major platelet, and 2 major neutrophil. Confirmed responses were seen after 2 to 6.1 months of treatment and lasted from 2 to >8 months on study, with 1 pt maintaining response for >21 months off study. Four TD pts became transfusion-independent, and transfusion requirements in 3 others decreased by ¡Ý50%. Stable disease lasting >8 weeks was observed in 8 additional HR pts. Grades (gr) 3-4 adverse events considered drug-related that were observed in ¡Ý2 pts included fatigue, febrile neutropenia, dyspnea, urinary tract infection, hyperglycemia, congestive heart failure, hypoxia, herpes infection, and pleural effusion. Some cytopenias were exacerbated, resulting in 1 gr 3 and 2 gr 4 neutropenias, and 3 gr 3 and 1 gr 4 thrombocytopenias. Conclusions: ATO demonstrates multilineage hematopoietic activity in both LR and HR MDS pts. ATO is well tolerated, as most treatment-related adverse events were mild to moderate. Abstract No: 6512 Elbit Medical Imaging Ltd. Announces That Elscint Holding Gamida-Cell and Teva Will Develop and Commercialize StemEx(R) for the Treatment of Leukemia
As part of its investment in Gamida-Cell in 2003, Teva holds an option to jointly complete development and globally commercialize StemEx(R). Teva will invest, under certain conditions, up to $25 million in the joint venture. Currently, only 15% of patients requiring bone marrow transplantation, who do not have genetically matched relatives, are able to find matching donors. StemEx(R), which was developed by Gamida-Cell based on inventions from the Hadassah hospital in Jerusalem, is cord blood highly enriched with stem cells. Data from Gamida-Cell's Phase I/II study presented at the annual conference of the American Society for Hematologyin December 2004, demonstrated that StemEx(R) has the potential to fulfill a life saving need for the majority of patients who cannot find matching donors. Rachel Lavine, President and CEO of Elscint, commented: "As the largest shareholder in Gamida-Cell, we are pleased to see a prominent partner such as Teva recognize the potential of the company's science and partner with them to achieve their strategy of leading the Cell Therapy market." "Gamida-Cell is pleased to continue and expand its collaboration with Teva. It is our intention to begin a pivotal Phase II/III study of StemEx(R) and secure fast track designation," said Gamida-Cell CEO, Mr. Ehud Marom. "The execution of our agreement with Teva places Gamida-Cell in the lead of the emerging, multi billion dollar Cell Therapy market." Elscint Limited has interests in hotels in Western Europe, in hotel development projects principally in Western and Central Europe and in the Arena commercial and entertainment center in Israel. This release contains certain forward-looking statements which involve known and unknown risks, uncertainties or other factors not under the Company's control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include, but are not limited to, those detailed in the Company's periodic filings with the Securities and Exchange Commission. Company Contact: Investor Contact: ------------------------------------------------
|
|||||||||||||||||||
|
|